Urolithin A for Women: Energy, Strength & Healthy Aging

Women have specific reasons to care about mitochondrial health, particularly around the shifts of perimenopause and menopause. This is a clear-eyed look at what urolithin A is, what the human trials actually included, and how to think about it as structure-function support rather than a treatment for any life stage.

Why mitochondrial health matters for women in midlife

Muscle and energy are tightly linked to mitochondria, the tiny structures inside cells that turn food and oxygen into ATP, the body's usable energy. As we age, mitochondrial quality tends to decline: worn units accumulate and the cell's ability to recycle them slows. For women, this general aging pattern intersects with a distinct hormonal transition.

Research on menopause describes measurable changes in muscle during this window. Declining estrogen is associated with loss of muscle mass and strength, and some clinicians now describe a broader musculoskeletal syndrome of menopause that can include muscle and joint symptoms. Estradiol appears to play a role in muscle maintenance, which is part of why the perimenopausal and postmenopausal years are a period when many women become more attentive to preserving strength and stamina. None of this makes urolithin A a hormonal product or a menopause treatment, but it explains why mitochondrial and muscle support is a topic of genuine interest for women in midlife.

What urolithin A is

Urolithin A is a gut postbiotic. It is not found in food directly. Your gut microbiome produces it from ellagitannins, compounds in pomegranate, walnuts, and berries, and only some people carry the microbes needed to make meaningful amounts. That is a key point for women thinking about diet alone: two people eating the same pomegranate can end up with very different urolithin A levels. Once produced, it supports mitophagy, the recycling of worn-out mitochondria so that healthier ones can take their place.

What the human trials actually included

It is worth being precise about who was studied, because the relevance to women depends on it.

Mixed-sex trials in older and middle-aged adults (human)

The two foundational efficacy trials enrolled both women and men. Liu, D'Amico and colleagues (JAMA Network Open, 2022) studied older adults over roughly four months and reported improved muscle endurance, measured as contractions before fatigue. Singh and colleagues (Cell Reports Medicine, 2022) studied middle-aged adults over four months at 500 and 1,000 mg per day and reported improvements in muscle strength and exercise performance. These were general adult populations that included women, rather than women-specific studies.

Safety and mitochondrial engagement in people (human)

The first-in-human study (Andreux 2019, Nature Metabolism) established that urolithin A was safe and well tolerated up to 1,000 mg per day and produced a measurable mitochondrial gene-expression signature. A 2025 randomized trial in Nature Aging (about 28 days) reported support for the mitochondrial health of immune cells in midlife adults, in the context of inflammaging, the low-grade inflammation associated with aging.

Newer athletic trials and the mechanistic base (human and preclinical)

Two 2024 to 2025 trials examined trained populations, resistance-trained adults and distance runners, looking at endurance and recovery markers; these are newer and smaller. Underneath all of this sits the foundational mechanism work, Ryu and colleagues (Nature Medicine, 2016), which demonstrated mitophagy, extended lifespan in the roundworm C. elegans, and improved muscle function in rodents. That work is preclinical, animal and cell research, and explains the mechanism rather than proving human outcomes. A separate line of preclinical work (D'Amico 2022, Aging Cell) is exploring joint and cartilage mitochondrial health in osteoarthritis models, which is early animal research and not human proof.

The honest summary: there is no large trial designed specifically around women or menopause. What exists is solid human evidence in mixed-sex adult populations, which included women, plus a strong mechanistic foundation. To date, the muscle and energy trials did not report meaningfully different results by sex, but women-specific research remains an open area.

How to think about it during perimenopause and menopause

Framed correctly, urolithin A is structure-function support for muscle and mitochondrial health during a stage of life when both are under more pressure. It supports the cellular energy machinery and mitochondrial recycling; it is not a hormone, not a replacement for hormone therapy, and not a treatment for menopause symptoms. It pairs most sensibly with the strategies that have the deepest evidence for midlife muscle and energy: resistance training, adequate protein, and sleep. Urolithin A supports those efforts rather than replacing them. To understand the biology, see our overviews of mitochondrial health and mitophagy, and our focused pages on urolithin A for muscle and urolithin A for energy.

Not a treatment — see your doctor

Menopause, perimenopause, and midlife fatigue involve real physiology, and decisions about them belong with your healthcare provider. Urolithin A is a structure-function supplement; it is not intended to diagnose, treat, or prevent menopause, its symptoms, or any medical condition. If you are pregnant, trying to conceive, breastfeeding, taking medications, or managing a health condition, talk to your doctor before starting any new supplement. Persistent or new symptoms, including fatigue, muscle weakness, or joint pain, deserve a medical evaluation rather than self-treatment.

Honest limitations

A 2024 systematic review in Ageing Research Reviews concluded that human evidence for urolithin A is still emerging, with trials that are short and modest in size. There is no menopause-specific efficacy trial. The muscle and energy findings come from mixed-sex adult populations and are best described as supportive and gradual, with responses that vary between individuals, partly because natural urolithin A production differs so widely.

Practical guidance

The studied daily amount is 500 to 1,000 mg. SOMA HEALTH Urolithin A Gummies are formulated at 1,000 mg per 4-gummy serving, the upper end of that range. Take it consistently every day, pair it with strength training and protein, and evaluate it over months. For the complete background, read our urolithin A guide; to compare products, see our roundup of the best urolithin A gummies; and for routine, how to take urolithin A.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This guide is educational and is not a substitute for advice from a qualified healthcare provider.